

Elisa Menegatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1364926/publications.pdf>

Version: 2024-02-01

52
papers

1,049
citations

331259

21
h-index

454577

30
g-index

52
all docs

52
docs citations

52
times ranked

1700
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. <i>Autoimmunity Reviews</i> , 2018, 17, 1138-1149.	2.5	88
2	New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature. <i>Autoimmunity Reviews</i> , 2016, 15, 529-538.	2.5	64
3	Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3987-3992.	0.4	61
4	Rituximab in cryoglobulinemic peripheral neuropathy. <i>Journal of Neurology</i> , 2009, 256, 1076-1082.	1.8	54
5	A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatmentâ€”Clinical response compared to literature and immunological re-assessment. <i>Autoimmunity Reviews</i> , 2015, 14, 1123-1130.	2.5	52
6	Common variable immunodeficiency: Crossroads between infections, inflammation and autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 796-801.	2.5	49
7	4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. <i>Free Radical Biology and Medicine</i> , 2006, 40, 1578-1591.	1.3	38
8	Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. <i>American Journal of Nephrology</i> , 2016, 43, 251-260.	1.4	38
9	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. <i>Clinical and Molecular Allergy</i> , 2016, 14, 6.	0.8	37
10	Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis. <i>American Journal of Nephrology</i> , 2011, 34, 175-180.	1.4	35
11	Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. <i>Frontiers in Immunology</i> , 2019, 10, 376.	2.2	34
12	Absence of NF-Î²B Activation by a New Polystyrene-Type Adsorbent Designed for Hemoperfusion. <i>Blood Purification</i> , 2005, 23, 91-98.	0.9	32
13	The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. <i>Oncotarget</i> , 2017, 8, 41764-41777.	0.8	28
14	4-Hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity. <i>Journal of Nutritional Biochemistry</i> , 2010, 21, 818-826.	1.9	27
15	8-Isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. <i>Inflammation Research</i> , 2012, 61, 809-816.	1.6	27
16	Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort. <i>BMJ Open</i> , 2017, 7, e015243.	0.8	26
17	High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. <i>American Journal of Nephrology</i> , 2017, 46, 108-113.	1.4	24
18	Spontaneous remission in a Diamondâ€”Blackfan anaemia patient due to a revertant uniparental disomy ablating a <i>de novo</i> RPS19 mutation. <i>British Journal of Haematology</i> , 2019, 185, 994-998.	1.2	24

#	ARTICLE	IF	CITATIONS
19	Polymorphism of the Uteroglobin Gene in Systemic Lupus Erythematosus and IgA Nephropathy. Laboratory Investigation, 2002, 82, 543-546.	1.7	23
20	PPAR β ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. Journal of Cellular and Molecular Medicine, 2010, 14, 1347-1357.	1.6	23
21	Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget, 2018, 9, 28799-28804.	0.8	23
22	Possible role for interleukins as biomarkers for mortality and recurrence in oral cancer. International Journal of Biological Markers, 2015, 30, 262-266.	0.7	22
23	Lab-on-a-chip: Emerging analytical platforms for immune-mediated diseases. Autoimmunity Reviews, 2013, 12, 814-820.	2.5	19
24	Genetic Factors Associated with Rheumatoid Arthritis and Systemic Vasculitis: Evaluation of a Panel of Polymorphisms. Disease Markers, 2009, 27, 217-223.	0.6	18
25	The ϵ 4 plus 2 ϵ rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. Oncotarget, 2017, 8, 52072-52077.	0.8	15
26	Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network. Italian Journal of Pediatrics, 2020, 46, 130.	1.0	14
27	Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. Autoimmunity Reviews, 2020, 19, 102641.	2.5	13
28	Intradialytic Cytokine Gene Expression. Blood Purification, 1998, 16, 30-36.	0.9	12
29	Classic and Perinuclear Anti-Neutrophil Cytoplasm Antibodies and Antimyeloperoxidase Antibodies in Rapidly Progressive Glomerulonephritis. American Journal of Nephrology, 1991, 11, 318-324.	1.4	11
30	Treatment of antiphospholipid syndrome. Clinical Immunology, 2020, 221, 108597.	1.4	11
31	Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. International Journal of Molecular Sciences, 2020, 21, 9551.	1.8	11
32	Genetic factors associated with rheumatoid arthritis and systemic vasculitis: Evaluation of a panel of polymorphisms. Disease Markers, 2009, 27, 217-23.	0.6	11
33	Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2013, 757, 104-113.	0.9	10
34	Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring. Autoimmunity Reviews, 2020, 19, 102449.	2.5	10
35	Variants in <i>ATP6VOA1</i> cause progressive myoclonus epilepsy and developmental and epileptic encephalopathy. Brain Communications, 2021, 3, fcb245.	1.5	10
36	Safety of outpatient percutaneous native renal biopsy in systemic autoimmune diseases: results from a monocentric cohort. Lupus, 2018, 27, 1393-1394.	0.8	7

#	ARTICLE	IF	CITATIONS
37	The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low risk for chromosomal abnormalities. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2921-2928.	1.9	7
38	Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. <i>Frontiers in Immunology</i> , 2021, 12, 769785.	2.2	6
39	Immunogenetics of complement in mixed cryoglobulinaemia. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S12-5.	0.4	6
40	It is the goal of this section to publish material that provides information regarding specific issues, aspects of artificial organ application, approach, philosophy, suggestions, and/or thoughts for the future. 5-Lipoxygenase Gene Expression in Hemodialysis. <i>Artificial Organs</i> , 1998, 22, 140-142.	1.0	5
41	Cytokine Release Pathway in Mononuclear Cells Stimulated in vitro by Dialysis Membranes. <i>American Journal of Nephrology</i> , 2002, 22, 509-514.	1.4	5
42	Circulating microRNAs as potential biomarkers for monitoring the response to in vivo treatment with Rituximab in systemic lupus erythematosus patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102488.	2.5	5
43	Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies. <i>Immunologic Research</i> , 2021, 69, 372-377.	1.3	4
44	Piedmont and Aosta Valley inter-regional network in the context of the Italian National Network for rare diseases. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s617-20.	0.3	4
45	Immunological Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 497-509.	0.8	2
46	Relationship between cryoglobulinemia-associated nephritis and HCV infection. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 515-524.	1.3	1
47	The Glu331del mutation in the CYP17A1 gene causes atypical congenital adrenal hyperplasia in a 46,XX female. <i>Gynecological Endocrinology</i> , 2017, 33, 918-922.	0.7	1
48	Immunotherapies in phase II and III trials for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 55-69.	0.5	1
49	Translational validation of the Global Antiphospholipid Syndrome Score in patients with thrombotic APS. <i>Rheumatology</i> , 2019, 58, 1870-1872.	0.9	1
50	Effects of ANCA-Positive Sera on the Generation of Oxygen Free Radicals by Neutrophils. <i>Contributions To Nephrology</i> , 1992, 99, 108-113.	1.1	0
51	Somatic Mosaicism and Variable Expressivity in Diamond Blackfan Anemia (DBA): A Large Deletion Involving the 19q13 Locus in a Patient with Transient Anemia. <i>Blood</i> , 2005, 106, 3550-3550.	0.6	0
52	SAT-346 POR Rs2286822 Polymorphism Is Associated with Clinical Features in Patients with Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0